Sign Out
Hepatocellular carcinoma: Sorafenib is indicated for the treatment of hepatocellular carcinoma who are unable to undergo surgery and in whom local chemotherapy is unsuitable. Consult hepatobiliary cancer practice guideline for more details.
Renal cell carcinoma: Sorafenib is indicated for the treatment of patients with advanced renal cell carcinoma.
Differentiated thyroid carcinoma: Sorafenib is indicated for the treatment of patients with locally advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine.
Continue with Google